Cocrystal Pharma Inc. (COCP)
1.34
0.01 (0.75%)
At close: Apr 15, 2025, 3:57 PM
1.34
-0.08%
After-hours: Apr 15, 2025, 04:01 PM EDT
0.75% (1D)
| Bid | 1.22 |
| Market Cap | 13.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.5M |
| EPS (ttm) | -1.72 |
| PE Ratio (ttm) | -0.78 |
| Forward PE | -0.52 |
| Analyst | Buy |
| Ask | 1.49 |
| Volume | 4,544 |
| Avg. Volume (20D) | 23,131 |
| Open | 1.38 |
| Previous Close | 1.33 |
| Day's Range | 1.33 - 1.40 |
| 52-Week Range | 1.12 - 3.26 |
| Beta | 2.21 |
About COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical tri...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 22, 2012
Employees 11
Stock Exchange NASDAQ
Ticker Symbol COCP
Website https://www.cocrystalpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for COCP stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 422.39% from the latest price.
Stock Forecasts3 months ago
+6.64%
Cocrystal Pharma shares are trading higher after t...
Unlock content with
Pro Subscription
3 months ago
-37.85%
Cocrystal Pharma shares are trading lower after the company announced disappointing low infectivity rates for the Oral PB2 inhibitor CC-42344 and will extend its Phase 2a influenza challenge study.
